Tolterodine

As effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder

Jeong Gu Lee, Jae Yup Hong, Myung Soo Choo, Hun Young Kwon, Do Young Chung, Kyu Sung Lee, Ji Youl Lee, Tack Lee

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background: This double-blind, multicenter study compared the efficacy and tolerability of tolterodine (Pharmacia, Los Angeles, USA) with that of oxybutynin (Alza, Palo Alto, USA) in Asian patients with overactive bladder. Methods: Two-hundred-and-twenty-eight adults with overactive bladder symptoms were randomized to receive tolterodine 2 mg twice daily (bid) (n = 112) or oxybutynin 5 mg bid (n = 116). After 8 weeks' treatment, changes in micturition diary variables, patients' perception of treatment benefit, and tolerability endpoints were determined. Results: The mean (±SD) number of micturitions/24 h decreased by 2.6 ± 2.9 (-21%) with tolterodine and 1.8 ± 4.2 (-15%) with oxybutynin (both P = 0.0001 vs baseline). The mean number of incontinence episodes/24 h decreased by 2.2 ± 2.3 (-85%) in the tolterodine group and by 1.4 ± 1.8 (-58%) in the oxybutynin group (both P = 0.0001 vs baseline). Patient perception of treatment benefit was over 70% in each treatment group. Adverse events were significantly lower in the tolterodine group compared with oxybutynin-treated patients (55% vs 82%; P = 0.001). Dry mouth was reported by significantly fewer patients on tolterodine, compared with oxybutynin (35% vs 63%; P = 0.001) and withdrawals due to adverse events were lower in the tolterodine group than with those treated with oxybutynin (10% vs 16%). There were no safety concerns. Conclusions: Tolterodine 2 mg bid is equally or more effective than oxybutynin 5 mg bid in the treatment of Asian patients with overactive bladder, and shows significantly better tolerability. This may enhance compliance during long-term treatment.

Original languageEnglish
Pages (from-to)247-252
Number of pages6
JournalInternational Journal of Urology
Volume9
Issue number5
DOIs
Publication statusPublished - 2002 Jun 26

Fingerprint

Overactive Urinary Bladder
Urination
Therapeutics
Los Angeles
Tolterodine Tartrate
oxybutynin
Double-Blind Method
Compliance
Multicenter Studies
Mouth
Safety

Keywords

  • Overactive bladder
  • Oxybutynin
  • Tolterodine

ASJC Scopus subject areas

  • Urology

Cite this

Tolterodine : As effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. / Lee, Jeong Gu; Hong, Jae Yup; Choo, Myung Soo; Kwon, Hun Young; Chung, Do Young; Lee, Kyu Sung; Lee, Ji Youl; Lee, Tack.

In: International Journal of Urology, Vol. 9, No. 5, 26.06.2002, p. 247-252.

Research output: Contribution to journalArticle

Lee, Jeong Gu ; Hong, Jae Yup ; Choo, Myung Soo ; Kwon, Hun Young ; Chung, Do Young ; Lee, Kyu Sung ; Lee, Ji Youl ; Lee, Tack. / Tolterodine : As effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. In: International Journal of Urology. 2002 ; Vol. 9, No. 5. pp. 247-252.
@article{175ddd3164944c5b9a11a921969c3dae,
title = "Tolterodine: As effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder",
abstract = "Background: This double-blind, multicenter study compared the efficacy and tolerability of tolterodine (Pharmacia, Los Angeles, USA) with that of oxybutynin (Alza, Palo Alto, USA) in Asian patients with overactive bladder. Methods: Two-hundred-and-twenty-eight adults with overactive bladder symptoms were randomized to receive tolterodine 2 mg twice daily (bid) (n = 112) or oxybutynin 5 mg bid (n = 116). After 8 weeks' treatment, changes in micturition diary variables, patients' perception of treatment benefit, and tolerability endpoints were determined. Results: The mean (±SD) number of micturitions/24 h decreased by 2.6 ± 2.9 (-21{\%}) with tolterodine and 1.8 ± 4.2 (-15{\%}) with oxybutynin (both P = 0.0001 vs baseline). The mean number of incontinence episodes/24 h decreased by 2.2 ± 2.3 (-85{\%}) in the tolterodine group and by 1.4 ± 1.8 (-58{\%}) in the oxybutynin group (both P = 0.0001 vs baseline). Patient perception of treatment benefit was over 70{\%} in each treatment group. Adverse events were significantly lower in the tolterodine group compared with oxybutynin-treated patients (55{\%} vs 82{\%}; P = 0.001). Dry mouth was reported by significantly fewer patients on tolterodine, compared with oxybutynin (35{\%} vs 63{\%}; P = 0.001) and withdrawals due to adverse events were lower in the tolterodine group than with those treated with oxybutynin (10{\%} vs 16{\%}). There were no safety concerns. Conclusions: Tolterodine 2 mg bid is equally or more effective than oxybutynin 5 mg bid in the treatment of Asian patients with overactive bladder, and shows significantly better tolerability. This may enhance compliance during long-term treatment.",
keywords = "Overactive bladder, Oxybutynin, Tolterodine",
author = "Lee, {Jeong Gu} and Hong, {Jae Yup} and Choo, {Myung Soo} and Kwon, {Hun Young} and Chung, {Do Young} and Lee, {Kyu Sung} and Lee, {Ji Youl} and Tack Lee",
year = "2002",
month = "6",
day = "26",
doi = "10.1046/j.1442-2042.2002.00460.x",
language = "English",
volume = "9",
pages = "247--252",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Tolterodine

T2 - As effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder

AU - Lee, Jeong Gu

AU - Hong, Jae Yup

AU - Choo, Myung Soo

AU - Kwon, Hun Young

AU - Chung, Do Young

AU - Lee, Kyu Sung

AU - Lee, Ji Youl

AU - Lee, Tack

PY - 2002/6/26

Y1 - 2002/6/26

N2 - Background: This double-blind, multicenter study compared the efficacy and tolerability of tolterodine (Pharmacia, Los Angeles, USA) with that of oxybutynin (Alza, Palo Alto, USA) in Asian patients with overactive bladder. Methods: Two-hundred-and-twenty-eight adults with overactive bladder symptoms were randomized to receive tolterodine 2 mg twice daily (bid) (n = 112) or oxybutynin 5 mg bid (n = 116). After 8 weeks' treatment, changes in micturition diary variables, patients' perception of treatment benefit, and tolerability endpoints were determined. Results: The mean (±SD) number of micturitions/24 h decreased by 2.6 ± 2.9 (-21%) with tolterodine and 1.8 ± 4.2 (-15%) with oxybutynin (both P = 0.0001 vs baseline). The mean number of incontinence episodes/24 h decreased by 2.2 ± 2.3 (-85%) in the tolterodine group and by 1.4 ± 1.8 (-58%) in the oxybutynin group (both P = 0.0001 vs baseline). Patient perception of treatment benefit was over 70% in each treatment group. Adverse events were significantly lower in the tolterodine group compared with oxybutynin-treated patients (55% vs 82%; P = 0.001). Dry mouth was reported by significantly fewer patients on tolterodine, compared with oxybutynin (35% vs 63%; P = 0.001) and withdrawals due to adverse events were lower in the tolterodine group than with those treated with oxybutynin (10% vs 16%). There were no safety concerns. Conclusions: Tolterodine 2 mg bid is equally or more effective than oxybutynin 5 mg bid in the treatment of Asian patients with overactive bladder, and shows significantly better tolerability. This may enhance compliance during long-term treatment.

AB - Background: This double-blind, multicenter study compared the efficacy and tolerability of tolterodine (Pharmacia, Los Angeles, USA) with that of oxybutynin (Alza, Palo Alto, USA) in Asian patients with overactive bladder. Methods: Two-hundred-and-twenty-eight adults with overactive bladder symptoms were randomized to receive tolterodine 2 mg twice daily (bid) (n = 112) or oxybutynin 5 mg bid (n = 116). After 8 weeks' treatment, changes in micturition diary variables, patients' perception of treatment benefit, and tolerability endpoints were determined. Results: The mean (±SD) number of micturitions/24 h decreased by 2.6 ± 2.9 (-21%) with tolterodine and 1.8 ± 4.2 (-15%) with oxybutynin (both P = 0.0001 vs baseline). The mean number of incontinence episodes/24 h decreased by 2.2 ± 2.3 (-85%) in the tolterodine group and by 1.4 ± 1.8 (-58%) in the oxybutynin group (both P = 0.0001 vs baseline). Patient perception of treatment benefit was over 70% in each treatment group. Adverse events were significantly lower in the tolterodine group compared with oxybutynin-treated patients (55% vs 82%; P = 0.001). Dry mouth was reported by significantly fewer patients on tolterodine, compared with oxybutynin (35% vs 63%; P = 0.001) and withdrawals due to adverse events were lower in the tolterodine group than with those treated with oxybutynin (10% vs 16%). There were no safety concerns. Conclusions: Tolterodine 2 mg bid is equally or more effective than oxybutynin 5 mg bid in the treatment of Asian patients with overactive bladder, and shows significantly better tolerability. This may enhance compliance during long-term treatment.

KW - Overactive bladder

KW - Oxybutynin

KW - Tolterodine

UR - http://www.scopus.com/inward/record.url?scp=0036579980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036579980&partnerID=8YFLogxK

U2 - 10.1046/j.1442-2042.2002.00460.x

DO - 10.1046/j.1442-2042.2002.00460.x

M3 - Article

VL - 9

SP - 247

EP - 252

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 5

ER -